Latest Headlines

Latest Headlines

Tesaro's shares are routed on late-stage cancer drug data

Tesaro touted positive results for the primary endpoints laid out for the late-stage program it had underway for its top cancer drug prospect rolapitant, but investors soured on the drug after it failed to score secondary goals and drove the biotech's shares down by a hefty 22% this morning.

Tesaro insiders pledge support for $86M IPO gamble

Tesaro is betting that its management's rep and a late-stage program will help entice investors to snap up 6 million shares at $12 to $15 a share, worth an estimated $86.3 million.

Tesaro promises rapid progress with cancer drugs in $86M IPO

Tesaro has put together an SEC filing that makes one essential promise to prospective investors: This company is built for speed.